Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
2,225 stopped studies mapped to Malignant Genitourinary System Neoplasm and descendants · 88% state a reason
Over the 2,225 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04607135 | ARFI Imaging for Targeted Prostate Biopsy | N/A | terminated | Oct 29, 2020 | Duke University | Current sample size sufficiently powers the study to evaluate outcome measures | Other (stated, no rule matched) |
| NCT02569957 | Effect of Acetylcysteine With Topotecan Hydrochloride on the Tumor Microenvironment in… | Phase 2 | terminated | Oct 7, 2015 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | The trial was halted prematurely due to slow accrual. | Enrollment / accrual |
| NCT01341288 | Robotic Seed Implantation for Prostate Cancer Brachytherapy(EUCLIDIAN) | Phase 1 | terminated | Apr 25, 2011 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Slow accrual | Enrollment / accrual |
| NCT02671552 | Contrast-Enhanced Ultrasound in Predicting Treatment Response in Patients With Kidney… | Early Phase 1 | withdrawn | Feb 2, 2016 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Terminated by the IRB | Other (stated, no rule matched) |
| NCT01313559 | Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone… | Phase 2 | terminated | Mar 11, 2011 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Slow accrual | Enrollment / accrual |
| NCT05462249 | Impact of Catch-up HPV Vaccination(HPVAC2) | — | terminated | Jul 18, 2022 | University Hospital, Brest | overestimation of the number of healthcare professionals participating in the inclusions | Other (stated, no rule matched) |
| NCT03076242 | Genetic Evaluation of Men (GEM) | — | terminated | Mar 10, 2017 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Competing trial | Other (stated, no rule matched) |
| NCT03477864 | Stereotactic Body Radiation Therapy With REGN2810 and/or Ipilimumab Before Surgery in… | Phase 1 | withdrawn | Mar 26, 2018 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Study was not accruing | Enrollment / accrual |
| NCT04483544 | Pembrolizumab and Olaparib in Cervical Cancer Patients | Phase 2 | terminated | Jul 23, 2020 | Baptist Health South Florida | Poor accrual related to change in standard of care treatment for this population. | Enrollment / accrual |
| NCT05819827 | Associations Between Chemotherapy-Induced Nausea in Patients With Genitourinary, Sarcoma… | — | terminated | Apr 19, 2023 | Mayo Clinic | Low/slow accrual | Enrollment / accrual |
| NCT06795178 | Efficacy, Safety, and Pharmacokinetics of FP-014, 11.25 mg in Patients With Advanced…(KATANA E3M) | Phase 3 | withdrawn | Jan 27, 2025 | Foresee Pharmaceuticals Co., Ltd. | Business reasons not safety related. | Safety / toxicity |
| NCT06795191 | Efficacy, Safety, and Pharmacokinetics of FP-014, 22.5 mg in Patients With Advanced…(KATANA E6M) | Phase 3 | withdrawn | Jan 27, 2025 | Foresee Pharmaceuticals Co., Ltd. | Business reasons not safety related. | Safety / toxicity |
| NCT02122172 | Afatinib in Advanced Refractory Urothelial Cancer | Phase 2 | terminated | Apr 24, 2014 | University of Chicago | Unable to meet accrual goal after several years | Enrollment / accrual |
| NCT06106633 | Pain Reduction and Ovarian Perfusion Following Uterine Fibroid Embolization(PEDD-UFE) | N/A | terminated | Oct 30, 2023 | Massachusetts General Hospital | Insufficient Enrollment | Enrollment / accrual |
| NCT03581500 | Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic Imaging in… | Phase 2 | withdrawn | Jul 10, 2018 | M.D. Anderson Cancer Center | Committee could not find that the regulatory approval are met to re-approve this study. | Other (stated, no rule matched) |
| NCT04301011 | Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors(RAPTOR) | Phase 1 | terminated | Mar 9, 2020 | Turnstone Biologics, Corp. | Sponsor decision | Sponsor / business decision |
| NCT04514692 | Bone Marrow Sparing Image-Guided Radiation Therapy (RT) Incorporating Novel Use of GCSF… | Phase 1 / Phase 2 | terminated | Aug 17, 2020 | Stanford University | Lack of funding | Funding |
| NCT04875806 | A Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid… | Phase 1 / Phase 2 | terminated | May 6, 2021 | NextCure, Inc. | Due to the limited activity in Phase 1, NextCure decided to discontinue development of the… | Other (stated, no rule matched) |
| NCT04278326 | Primary Organoid Models and Combined Nucleic Acids Therapeutics for Anti-HPV Treatments(ORGANOIDES) | N/A | terminated | Feb 20, 2020 | Centre Hospitalier Régional d'Orléans | the partner laboratory encountered various difficulties (COVID, relocation of the laboratory,… | COVID-19 / pandemic |
| NCT03610490 | Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or… | Phase 2 | terminated | Aug 1, 2018 | M.D. Anderson Cancer Center | Lack of Efficacy | Efficacy / futility |
| NCT05179239 | A Study of SHR-1701 Plus Platinum-containing Chemotherapy With or Without BP102… | Phase 3 | terminated | Jan 5, 2022 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Sponsor develops strategy adjustment | Sponsor / business decision |
| NCT03764540 | Docetaxel Versus Cabazitaxel Post Abiraterone or Enzalutamide(CABPOSTAAT) | Phase 2 | terminated | Dec 5, 2018 | Centre hospitalier de l'Université de Montréal (CHUM) | The cabazitaxel was recently approved by the regulatory authorities for mCRPCa | Other (stated, no rule matched) |
| NCT05815316 | 18F-PSMA PET/MRI for the Diagnosis of Clinically Significant Prostate Cancer | Phase 2 | withdrawn | Apr 18, 2023 | IRCCS San Raffaele | error in the registration on clincialtrials.gov. The same clinical trial has been correctly… | Other (stated, no rule matched) |
| NCT05940844 | Study of OB-002 in Patients With Refractory Metastatic Cancer | Phase 1 | withdrawn | Jul 11, 2023 | Orion Biotechnology Polska Sp. z o.o. | study terminated due to changes in the drug development plan | Other (stated, no rule matched) |
| NCT04556617 | PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With… | Phase 1 / Phase 2 | terminated | Sep 21, 2020 | Opna Bio LLC | study terminated due to business realignment | Sponsor / business decision |
| NCT04067544 | Acupuncture Treatment of Chemotherapy-Induced Peripheral Neuropathy in Women | N/A | terminated | Aug 26, 2019 | University of Utah | Unforeseen complications due to COVID-19 and funding | COVID-19 / pandemic |
| NCT05126342 | Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After… | Phase 2 | withdrawn | Nov 19, 2021 | AGO Research GmbH | Study has been withdrawn; was never submitted to Competent authority nor to ethics commitee. | Other (stated, no rule matched) |
| NCT03527264 | BrUOG 355: Nivolumab to Tailored Radiation Therapy With Concomitant Cisplatin in the… | Phase 2 | terminated | May 17, 2018 | Brown University | Slow enrollment | Enrollment / accrual |
| NCT06422312 | A Study Comparing a Disposable Flexible Cystoscope With Reusable Scopes in Adult Patients. | N/A | withdrawn | May 20, 2024 | Guangzhou Red Pine Medical Instrument Co., Ltd. | A change in marketing strategy resulted in a decision to not complete the trial. | Sponsor / business decision |
| NCT04383210 | Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid… | Phase 2 | terminated | May 12, 2020 | Elevation Oncology | Business decision | Sponsor / business decision |
| NCT03829501 | A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab… | Phase 1 / Phase 2 | terminated | Feb 4, 2019 | Kymab Limited | Early discontinuation based on strategic sponsor decision not driven by any safety concerns. | Safety / toxicity |
| NCT06375629 | ES-HIFU, Prospective Data Collection of Patients Treated With Partial Gland HIFU Ablation…(ES-HIFU) | — | terminated | Apr 19, 2024 | EDAP TMS S.A. | The study was terminated early to integrate sites into a larger registry for a more comprehensive… | Safety / toxicity |
| NCT05208229 | The Role of WB-MRI in the Evaluation of Prostate Cancer Patients Treated With Lutetium -…(WB-LuPSMA) | — | terminated | Jan 26, 2022 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | The study was linked to another protocol that is over | Other (stated, no rule matched) |
| NCT06094842 | Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen… | Phase 1 | withdrawn | Oct 23, 2023 | Fred Hutchinson Cancer Center | Study closed before opening to accrual | Enrollment / accrual |
| NCT06385548 | Efficacy and Safety Study of Lurbinectedin and Dostarlimab in Cancer Patients: Protocol…(LiDer) | Phase 1 / Phase 2 | withdrawn | Apr 26, 2024 | Vall d'Hebron Institute of Oncology | IMP owner decision | Other (stated, no rule matched) |
| NCT05192850 | Endometrial Cancer Recurrence in Patients Taking Metformin | — | withdrawn | Jan 14, 2022 | WellSpan Health | study was not started at WellSpan | Other (stated, no rule matched) |
| NCT03585764 | MOv19-BBz CAR T Cells in aFR Expressing Recurrent High Grade Serous Ovarian, Fallopian… | Phase 1 | terminated | Jul 13, 2018 | University of Pennsylvania | This study was halted prematurely due to recruitment barriers | Enrollment / accrual |
| NCT02641639 | FOCUS: PCC + Bevacizumab + CA4P Versus PCC + Bevacizumab + Placebo for Subjects With… | Phase 2 / Phase 3 | terminated | Dec 29, 2015 | Mateon Therapeutics | The study was terminated early due to the lack of efficacy and the study sponsor's decision to no… | Efficacy / futility |
| NCT02053662 | Biomarker Identification for Bladder Cancer Patients | — | terminated | Feb 4, 2014 | Ohio State University Comprehensive Cancer Center | No publishable data was acquired from the study and the primary researcher left over 5 years ago. | Other (stated, no rule matched) |
| NCT04267120 | Lenvatinib (LEN) in Combination With Pembrolizumab (KEYtruda) in Subjects With Locally… | Phase 2 | terminated | Feb 12, 2020 | Washington University School of Medicine | Slow enrollment with low accrual | Enrollment / accrual |
| NCT03164980 | QoL-Comparison Between Trabectedin/PLD and Pt-based Therapy in Patients With Pt-sensitive…(COMPASS) | Phase 4 | terminated | May 24, 2017 | North Eastern German Society of Gynaecological Oncology | A total of 204 patients were planned to be randomized. Due to slow recruitment of the trial, the… | Enrollment / accrual |
| NCT04382898 | PRO-MERIT (Prostate Cancer Messenger RNA Immunotherapy)(PRO-MERIT) | Phase 1 / Phase 2 | terminated | May 11, 2020 | BioNTech SE | Sponsor decision | Sponsor / business decision |
| NCT04298983 | Abemaciclib in Combination With Androgen Deprivation Therapy for Locally Advanced…(RAD 1805) | Phase 2 | terminated | Mar 6, 2020 | University of Alabama at Birmingham | Abemaciclib efficacy | Efficacy / futility |
| NCT04889495 | A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in… | — | withdrawn | May 17, 2021 | Pfizer | The study was withdrawn due to global supply chain issue. Zirabev was not launching in Korea. | Drug supply |
| NCT06884683 | Nivolumab Plus Metformin in Metastatic Renal Cell Carcinoma(NivoMet) | Phase 2 | terminated | Mar 19, 2025 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | slow enrollment | Enrollment / accrual |
| NCT06257758 | A Phase 1/2 Study of VIO-01 in Participants With Recurrent Solid Tumors | Phase 1 / Phase 2 | terminated | Feb 14, 2024 | Valerio Therapeutics | Business decision | Sponsor / business decision |
| NCT04629339 | Study of INCB086550 in Select Solid Tumors | Phase 2 | terminated | Nov 16, 2020 | Incyte Corporation | Strategic business decision to terminate the study effective immediately. This is due to a company… | Sponsor / business decision |
| NCT06643494 | Elimination of Prostate Cancer Treatment Side Effects Using a Nutraceutical | Phase 1 / Phase 2 | suspended | Oct 16, 2024 | Optimal Health Research | PPI currently unable to continue. | Other (stated, no rule matched) |
| NCT04032704 | A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors | Phase 2 | terminated | Jul 25, 2019 | Seagen Inc. | Study closed due to portfolio prioritization | Sponsor / business decision |
| NCT04696263 | Single-Port Versus Multi-Port Robotic Radical Prostatectomy | N/A | withdrawn | Jan 6, 2021 | Case Comprehensive Cancer Center | Study closure based on study population not found and not enough study staff | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated May 6, 2025source: clinicaltrials